| Assessment Status | Assessment Process Complete |
| HTA ID | - |
| Drug | Rivaroxaban |
| Brand | Xarelto® |
| Indication | For the prevention of stroke in atrial fibrillation. |
| Assessment Process | |
| Rapid review commissioned | 17/08/2011 |
| Rapid review completed | 31/08/2011 |
| Rapid review outcome | Full Pharmacoeconomic Evaluation Recommended |
| Full submission received from Applicant | 11/11/2021 |
| NCPE assessment completed | 02/04/2012 |
| NCPE assessment outcome | Reimbursement not Recommended |
The NCPE do not believe that rivaroxaban is cost effective for this indication at the submitted price.
19/06/2012
Following the NCPE pharmacoeconomic assessment (2/4/2012) the manufacturer reduced the price of rivaroxaban (23/5/2012). At this revised price we now consider rivaroxaban cost effective for this indication. A positive recommendation was made on the 19/06/2012.
